OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:...
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference LONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma...
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE...
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain OK-101 is the first drug candidate to...
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain Neuropathic corneal pain (NCP) is listed in...
OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease LONDON and NEW YORK, Aug. 27, 2024 (GLOBE...
OKYO Pharma CEO Interview to Air on Bloomberg TV LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Announces Chairman Acquires Shares LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a...
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE...
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP...
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease Encouraging 68% improvement in responder rate...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads